Breaking News

CDMO C3i Center is Manufacturing a Cell Therapy Product for Europe

C3i provides process development and manufacturing to phase 3 with the expected goal of commercial launch at the end of 2024.

C3i Center Inc., a contract development and manufacturing organizations (CDMO), is manufacturing a cell therapy product for Europe that is currently in phase II clinical trials. C3i Center Inc. offers full in-house services for the development and commercialization of cell and gene therapies, including CRO, regulatory, Qc testing, biomarker development and immune monitoring services for Canada, the U.S., and Europe. C3i manufactures from process development to phase 3 with the expected goal o...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters